The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Bisphosphonate therapy for osteogenesis imperfecta
Open accessAbstract
BACKGROUND: Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal type I collagen bone matrix which typically results in multiple fractures with little or no trauma. Bisphosphonates are used in an attempt to increase bone mineral density and reduce these fractures in people with osteogenesis imperfecta. This is an update of a previously published Cochrane Review. OBJECTIVES: To assess the effectiveness and safety of bisphosphonates in increasing bone mineral density, reducing fractures and improving clinical function in people with osteogenesis imperfecta. SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of journals and conference proceedings. We additionally searched PubMed and major conference proceedings.Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Register: 28 April 2016. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials comparing bisphosphonates to placebo, no treatment, or comparator interventions in all types of osteogenesis imperfecta. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed the risk of bias of the included trials. MAIN RESULTS: Fourteen trials (819 participants) were included. Overall, the trials were mainly at a low risk of bias, although selective reporting was an issue in several of the trials. Data for oral bisphosphonates versus placebo could not be aggregated; a statistically significant difference favouring oral bisphosphonates in fracture risk reduction and number of fractures was noted in two trials. No differences were reported in the remaining three trials which commented on fracture incidence. Five trials reported data for spine bone mineral density; all found statistically significant increased lumbar spine density z scores for at least one time point studied. For intravenous bisphosphonates versus placebo, aggregated data from two trials showed no statistically significant difference for the number of participants with at least one fracture, risk ratio 0.56 (95% confidence interval 0.30 to 1.06). In the remaining trial no statistically significant difference was noted in fracture incidence. For spine bone mineral density, no statistically significant difference was noted in the aggregated data from two trials, mean difference 9.96 (95% confidence interval -2.51 to 22.43). In the remaining trial a statistically significant difference in mean per cent change in spine bone mineral density z score favoured intravenous bisphosphonates at six and 12 months. Data describing growth, bone pain, and functional outcomes after oral or intravenous bisphosphonate therapy, or both, as compared to placebo were incomplete among all studies, but do not show consistent improvements in these outcomes. Two studies compared different doses of bisphosphonates. No differences were found between doses when bone mineral density, fractures, and height or length z score were assessed. One trial compared oral versus intravenous bisphosphonates and found no differences in primary outcomes. Two studies compared the intravenous bisphosphonates zoledronic acid and pamidronate. There were no significant differences in primary outcome. However, the studies were at odds as to the relative benefit of zoledronic acid over pamidronate for lumbosacral bone mineral density at 12 months. AUTHORS' CONCLUSIONS: Bisphophonates are commonly prescribed to individuals with osteogenesis imperfecta. Current evidence, albeit limited, demonstrates oral or intravenous bisphosphonates increase bone mineral density in children and adults with this condition. These were not shown to be different in their ability to increase bone mineral density. It is unclear whether oral or intravenous bisphosphonate treatment consistently decreases fractures, though multiple studies report this independently and no studies report an increased fracture rate with treatment. The studies included here do not show bisphosphonates conclusively improve clinical status (reduce pain; improve growth and functional mobility) in people with osteogenesis imperfecta. Given their current widespread and expected continued use, the optimal method, duration of therapy and long-term safety of bisphosphonate therapy require further investigation. In addition, attention should be given to long-term fracture reduction and improvement in quality of life indicators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
(2008) · Cited by 3,790
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Genetic heterogeneity in osteogenesis imperfecta.
Sillence, D. O., Senn, A., & Danks, D. M. (1979) · Journal of Medical Genetics · doi:10.1136/jmg.16.2.101 · Cited by 2,229
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease
Glorieux, F. H., Rauch, F., Plotkin, H., Ward, L., Travers, R., Roughley, P., Lalic, L., Glorieux, D. F., Fassier, F., & Bishop, N. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1650 · Cited by 516
Cabral, W. A., Chang, W., Barnes, A. M., Weis, M., Scott, M. A., Leikin, S., Makareeva, E., Kuznetsova, N. V., Rosenbaum, K. N., Tifft, C. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1968 · Cited by 486
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Becker, J., Semler, O., Gilissen, C., Li, Y., Bolz, H. J., Giunta, C., Bergmann, C., Rohrbach, M., Koerber, F., Zimmermann, K., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.01.015 · Cited by 362
Deficiency of Cartilage-Associated Protein in Recessive Lethal Osteogenesis Imperfecta
Barnes, A. M., Chang, W., Morello, R., Cabral, W. A., Weis, M., Eyre, D. R., Leikin, S., Makareeva, E., Kuznetsova, N., Uveges, T. E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063804 · Cited by 354
Christiansen, H. E., Schwarze, U., Pyott, S. M., AlSwaid, A., Al Balwi, M., Alrasheed, S., Pepin, M. G., Weis, M. A., Eyre, D. R., & Byers, P. H. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.034 · Cited by 352
Osteogenesis imperfecta: translation of mutation to phenotype.
Byers, P. H., Wallis, G. A., & Willing, M. C. (1991) · Journal of Medical Genetics · doi:10.1136/jmg.28.7.433 · Cited by 326
Byers, P. H., & Steiner, R. D. (1992) · Annual Review of Medicine · doi:10.1146/annurev.me.43.020192.001413 · Cited by 325
Self-citationAlanay, Y., Avaygan, H., Camacho, N., Utine, G. E., Boduroglu, K., Aktas, D., Alikasifoglu, M., Tuncbilek, E., Orhan, D., Bakar, F. T., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.02.022 · Cited by 319
PPIB Mutations Cause Severe Osteogenesis Imperfecta
van Dijk, F. S., Nesbitt, I. M., Zwikstra, E. H., Nikkels, P. G. J., Piersma, S. R., Fratantoni, S. A., Jimenez, C. R., Huizer, M., Morsman, A. C., Cobben, J. M., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.09.001 · Cited by 298
Lapunzina, P., Aglan, M., Temtamy, S., Caparrós-Martín, J. A., Valencia, M., Letón, R., Martínez-Glez, V., Elhossini, R., Amr, K., Vilaboa, N., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.05.016 · Cited by 289
A Single Recurrent Mutation in the 5′-UTR of IFITM5 Causes Osteogenesis Imperfecta Type V
Cho, T.-J., Lee, K.-E., Lee, S.-K., Song, S. J., Kim, K. J., Jeon, D., Lee, G., Kim, H.-N., Lee, H. R., Eom, H.-H., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.06.005 · Cited by 265
Semler, O., Garbes, L., Keupp, K., Swan, D., Zimmermann, K., Becker, J., Iden, S., Wirth, B., Eysel, P., Koerber, F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.06.011 · Cited by 241
Ward, L. M., Rauch, F., Whyte, M. P., D'Astous, J., Gates, P. E., Grogan, D., Lester, E. L., McCall, R. E., Pressly, T. A., Sanders, J. O., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0636 · Cited by 221
Self-citationSakkers, R., Kok, D., Engelbert, R., van Dongen, A., Jansen, M., Pruijs, H., Verbout, A., Schweitzer, D., & Uiterwaal, C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16101-1 · Cited by 221
Martínez-Glez, V., Valencia, M., Caparrós-Martín, J. A., Aglan, M., Temtamy, S., Tenorio, J., Pulido, V., Lindert, U., Rohrbach, M., Eyre, D., et al. (2012) · Human Mutation · doi:10.1002/humu.21647 · Cited by 219
Letocha, A. D., Cintas, H. L., Troendle, J. F., Reynolds, J. C., Cann, C. E., Chernoff, E. J., Hill, S. C., Gerber, L. H., & Marini, J. C. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050109 · Cited by 217
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
Orwoll, E. S., Shapiro, J., Veith, S., Wang, Y., Lapidus, J., Vanek, C., Reeder, J. L., Keaveny, T. M., Lee, D. C., Mullins, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71101 · Cited by 210
Pyott, S. M., Tran, T. T., Leistritz, D. F., Pepin, M. G., Mendelsohn, N. J., Temme, R. T., Fernandez, B. A., Elsayed, S. M., Elsobky, E., Verma, I., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.02.009 · Cited by 208
Bishop, N., Adami, S., Ahmed, S. F., Antón, J., Arundel, P., Burren, C. P., Devogelaer, J.-P., Hangartner, T., Hosszú, E., Lane, J. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61091-0 · Cited by 201
Self-citationBisphosphonate therapy for osteogenesis imperfecta
Phillipi, C. A., Remmington, T., & Steiner, R. D. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub2 · Cited by 171
Self-citationEffect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta
Orioli, I. M., Castilla, E. E., Scarano, G., & Mastroiacovo, P. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320590218 · Cited by 167
Do Bisphosphonates Make Children's Bones Better or Brittle?
Marini, J. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038103 · Cited by 163
Bisphosphonate therapy for osteogenesis imperfecta
Dwan, K. M., Phillipi, C. A., Steiner, R. D., & Basel, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub3 · Cited by 155
Self-citationIntravenous Neridronate in Adults With Osteogenesis Imperfecta
Adami, S., Gatti, D., Colapietro, F., Fracassi, E., Braga, V., Rossini, M., & Tatò, L. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.126 · Cited by 147
DiMeglio, L. A., & Peacock, M. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051006 · Cited by 145
Hearing Loss in Finnish Adults with Osteogenesis Imperfecta: A Nationwide Survey
Kuurila, K., Johansson, R. K., Kaitila, I., & Grenman, R. A. (2002) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348940211101014 · Cited by 140
Rauch, F., Munns, C. F., Land, C., Cheung, M., & Glorieux, F. H. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090213 · Cited by 126
Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta
Seikaly, M. G., Kopanati, S., Salhab, N., Waber, P. G., Patterson, D., Browne, R. H., & Herring, J. A. (2005) · Journal of Pediatric Orthopaedics · doi:10.1097/01.bpo.0000176162.78980.ed · Cited by 125
Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review
Castillo, H. A., & Samson‐Fang, L. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03222.x · Cited by 119
Chevrel, G., Schott, A., Fontanges, É., Charrin, J. E., Lina‐Granade, G., Duboeuf, F., Garnero, P., ARLOT, M. E., Raynal, C., & Meunier, P. J. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051015 · Cited by 114
GH in combination with bisphosphonate treatment in osteogenesis imperfecta
Antoniazzi, F., Monti, E., Venturi, G., Franceschi, R., Doro, F., Gatti, D., Zamboni, G., & Tatò, L. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0208 · Cited by 94
Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I
Gatti, D., Rossini, M., Viapiana, O., Povino, M. R., Liuzza, S., Fracassi, E., Idolazzi, L., & Adami, S. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9770-2 · Cited by 92
A Controlled Study of the Effects of Alendronate in a Growing Mouse Model of Osteogenesis Imperfecta
Camacho, N. P., Raggio, C., Doty, S. B., Root, L., Zraick, V., Ilg, W. A., Toledano, T. R., & Boskey, A. L. (2001) · Calcified Tissue International · doi:10.1007/s002230010045 · Cited by 89
Connor, J. M., Connor, R., Sweet, E. M., Gibson, A. A. M., Patrick, W. J. A., McNay, M. B., Redford, D., Opitz, J. M., & Reynolds, J. F. (1985) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320220205 · Cited by 87
Barros, E. R., Saraiva, G. L., Palomo, T., & Lazaretti‐Castro, M. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2012-0016 · Cited by 86
Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta
DiMeglio, L. A., Ford, L., McClintock, C., et al. (2004) · Bone · doi:10.1016/j.bone.2004.07.003 · Cited by 80
Advances in Osteogenesis Imperfecta
Cole, W. G. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200208000-00003 · Cited by 77
Bishop, N. J., Harrison, R., Ahmed, F., Shaw, N., Eastell, R., Campbell, M., Knowles, E., Hill, C., Hall, C. M., Chapman, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090712 · Cited by 68
Thornton, J., Ashcroft, D. M., Mughal, M. Z., Elliott, R. A., O'Neill, T. W., & Symmons, D. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2006.093997 · Cited by 52
Intravenous Bisphosphonate Therapy Increases Radial Width in Adults With Osteogenesis Imperfecta
Gatti, D., Viapiana, O., Lippolis, I., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050312 · Cited by 32
Cited by
Forlino, A., & Marini, J. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00728-x · Cited by 942
New perspectives on osteogenesis imperfecta
Forlino, A., Cabral, W. A., Barnes, A. M., & Marini, J. C. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.81 · Cited by 727
New Insights into Monogenic Causes of Osteoporosis
Mäkitie, R. E., Costantini, A., Kämpe, A., Alm, J. J., & Mäkitie, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00070 · Cited by 108
Pavón de Paz, I., Rosado Sierra, J. A., Pérez Blanco, C., Modroño Móstoles, N., Guijarro de Armas, G., & Navea Aguilera, C. (2019) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2019.02.001 · Cited by 5
Metadata
- Authors
- Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-10-19
- Volume
- 2016
- Issue
- 10
- Pages
- CD005088-CD005088
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1776641035
- Cited by
- 405
- References
- 50
- FWCI
- 30.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.